Details of the Drug

General Information of Drug (ID: DMTO13J)

Drug Name
Clonazepam
Synonyms
Antelepsin; Antilepsin; Chlonazepam; Cloazepam; Clonazepamum; Clonex; Clonopin; Iktorivil; Kenoket; Klonopin; Landsen; Lktorivil; Lonazep; Melzap; Paxam; Ravotril; Rivatril; Rivoril; Rivotril; Solfidin; Klonopin Rapidly Disintegrating; DF2374250; RO4023; Ro 4023; Ro 54023; Alti-Clonazepam; Clonazepamum [INN-Latin]; Klonopin (TN); Ravotril (TN); Rivatril (TN); Rivotril (TN); Ro 4-8180; Ro 5-4023; Ro-5-4023; Clonazepam (JP15/USP/INN); Clonazepam [USAN:INN:BAN:JAN]; Ro 5-4023/B-7; 1,3-Dihydro-5-(o-chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2-one; 1,3-Dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one; 5-(2-Chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one; 5-(2-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one; 5-(2-Chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 5-(2-Chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2(1H)-one; 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one; 5-(o-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one; 5-(o-Chlorophenyl)-7-nitro-1H-1,4-benzodiazepin-2(3H)-one; 5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Nitro-5-(2-chlorophenyl)-3H-1,4-benzodiazepin-2(1H)-one
Indication
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Approved [1], [2]
Seizure disorder 8A6Z Phase 2 [1], [3], [4]
Therapeutic Class
Anticonvulsants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 315.71
Topological Polar Surface Area (xlogp) 2.4
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 36.4 mcgh/L [5]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 18 mcg/L [5]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [6]
Bioavailability
The bioavailability of drug is 76-85% [5]
Clearance
The clearance of drug is 55 mL/min [7]
Elimination
Approximately 50-70% of a clonazepam dose is excreted in the urine and 10-30% is excreted in the feces as metabolites [7]
Half-life
The concentration or amount of drug in body reduced by one-half in 30 - 40 hours [8]
Metabolism
The drug is metabolized via the liver [8]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.42126 micromolar/kg/day [9]
Unbound Fraction
The unbound fraction of drug in plasma is 0.15% [10]
Vd
The volume of distribution (Vd) of drug is 3 L/kg [7]
Water Solubility
The ability of drug to dissolve in water is measured as 0.1 mg/mL [6]
Chemical Identifiers
Formula
C15H10ClN3O3
IUPAC Name
5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one
Canonical SMILES
C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl
InChI
InChI=1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)
InChIKey
DGBIGWXXNGSACT-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2802
ChEBI ID
CHEBI:3756
CAS Number
1622-61-3
DrugBank ID
DB01068
TTD ID
D0CP4E
INTEDE ID
DR0351
ACDINA ID
D00140

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gamma-aminobutyric acid receptor (GAR) TTNJYV2 NOUNIPROTAC Agonist [11], [12]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [13]
RNA cytidine acetyltransferase (hALP) DEZV4AP NAT10_HUMAN Substrate [14]
Oxygen-insensitive NADPH nitroreductase B (nfsB) DE0QLUZ NFSB_ECOLI Substrate [15]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Clonazepam
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Cenobamate DMGOVHA Moderate Increased metabolism of Clonazepam caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [47]
Stiripentol DMMSDOY Moderate Decreased metabolism of Clonazepam caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [48]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Clonazepam caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [49]
Coadministration of a Drug Treating the Disease Different from Clonazepam (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Minor Altered absorption of Clonazepam due to GI dynamics variation caused by Sodium bicarbonate. Acidosis [5C73] [50]
Arn-509 DMT81LZ Moderate Increased metabolism of Clonazepam caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [51]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Clonazepam and Oliceridine. Acute pain [MG31] [52]
Emapalumab DMZG5WL Moderate Altered metabolism of Clonazepam due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [51]
Siltuximab DMGEATB Moderate Altered metabolism of Clonazepam due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [51]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Clonazepam caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [53]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Clonazepam caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [54]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Clonazepam caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [54]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Clonazepam caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [55]
Tucatinib DMBESUA Moderate Decreased metabolism of Clonazepam caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [56]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Clonazepam and Dihydrocodeine. Chronic pain [MG30] [57]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Clonazepam caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [58]
MK-8228 DMOB58Q Moderate Decreased metabolism of Clonazepam caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [59]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Clonazepam and Esketamine. Depression [6A70-6A7Z] [60]
SODIUM CITRATE DMHPD2Y Minor Altered absorption of Clonazepam due to GI dynamics variation caused by SODIUM CITRATE. Discovery agent [N.A.] [50]
Tazemetostat DMWP1BH Moderate Increased metabolism of Clonazepam caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [61]
Boceprevir DMBSHMF Moderate Decreased metabolism of Clonazepam caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [62]
Telaprevir DMMRV29 Moderate Decreased metabolism of Clonazepam caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [63]
Rifapentine DMCHV4I Moderate Increased metabolism of Clonazepam caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [64]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Clonazepam caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [65]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Clonazepam caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [66]
Saquinavir DMG814N Moderate Decreased metabolism of Clonazepam caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [67]
Etravirine DMGV8QU Moderate Increased metabolism of Clonazepam caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [68]
Darunavir DMN3GCH Moderate Decreased metabolism of Clonazepam caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [69]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Clonazepam caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [70]
Crizotinib DM4F29C Moderate Decreased metabolism of Clonazepam caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [71]
Brigatinib DM7W94S Moderate Increased metabolism of Clonazepam caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [72]
Ceritinib DMB920Z Moderate Decreased metabolism of Clonazepam caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [51]
PF-06463922 DMKM7EW Moderate Increased metabolism of Clonazepam caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [73]
Selpercatinib DMZR15V Moderate Decreased metabolism of Clonazepam caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [51]
Idelalisib DM602WT Moderate Decreased metabolism of Clonazepam caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [74]
IPI-145 DMWA24P Moderate Decreased metabolism of Clonazepam caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [75]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Clonazepam caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [51]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Clonazepam and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [76]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Clonazepam and Lasmiditan. Migraine [8A80] [77]
Exjade DMHPRWG Moderate Decreased metabolism of Clonazepam caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [78]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Clonazepam and Flibanserin. Mood disorder [6A60-6E23] [79]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Clonazepam caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [51]
Nilotinib DM7HXWT Moderate Decreased metabolism of Clonazepam caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [80]
Dasatinib DMJV2EK Moderate Decreased metabolism of Clonazepam caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [81]
Teduglutide DMYOAKS Moderate Altered absorption of Clonazepam caused by Teduglutide. Neonatal malabsorption syndrome [KB89] [82]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Clonazepam and Levomethadyl Acetate. Opioid use disorder [6C43] [57]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Clonazepam caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [83]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Clonazepam and Oxymorphone. Pain [MG30-MG3Z] [52]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Clonazepam and Dezocine. Pain [MG30-MG3Z] [52]
Abametapir DM2RX0I Moderate Decreased metabolism of Clonazepam caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [84]
Lefamulin DME6G97 Moderate Decreased metabolism of Clonazepam caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [85]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Clonazepam caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [86]
Enzalutamide DMGL19D Moderate Increased metabolism of Clonazepam caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [87]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Clonazepam due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [51]
Ixekizumab DMXW92T Moderate Altered metabolism of Clonazepam due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [51]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Clonazepam and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [88]
Tocilizumab DM7J6OR Moderate Altered metabolism of Clonazepam due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [51]
Canakinumab DM8HLO5 Moderate Altered metabolism of Clonazepam due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [51]
Rilonacept DMGLUQS Moderate Altered metabolism of Clonazepam due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [51]
Golimumab DMHZV7X Moderate Altered metabolism of Clonazepam due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [51]
Sarilumab DMOGNXY Moderate Altered metabolism of Clonazepam due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [51]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Clonazepam caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [89]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Clonazepam caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [51]
Larotrectinib DM26CQR Moderate Decreased metabolism of Clonazepam caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [60]
Armodafinil DMGB035 Minor Increased metabolism of Clonazepam caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [90]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Clonazepam caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [91]
Amiodarone DMUTEX3 Minor Potentiate the pharmacologic effects by the combination of Clonazepam and Amiodarone. Ventricular tachyarrhythmia [BC71] [92]
⏷ Show the Full List of 63 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Aspartame E00402 134601 Flavoring agent
D&C red no. 30 E00456 3000709 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Hexahydric alcohol E00083 5780 Diluent; Flavoring agent; Humectant; Plasticizing agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Water E00035 962 Solvent
Xylitol E00136 6912 Coating agent; Diluent; Emollient; Flavoring agent; Humectant
⏷ Show the Full List of 20 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Clonazepam 0.125 mg tablet 0.125 mg Disintegrating Oral Tablet Oral
Clonazepam 0.25 mg tablet 0.25 mg Disintegrating Oral Tablet Oral
Clonazepam 0.5 mg tablet 0.5 mg Disintegrating Oral Tablet Oral
Clonazepam 1 mg tablet 1 mg Disintegrating Oral Tablet Oral
Clonazepam 2 mg tablet 2 mg Disintegrating Oral Tablet Oral
Clonazepam 0.5 mg tablet 0.5 mg Oral Tablet Oral
Clonazepam 1 mg tablet 1 mg Oral Tablet Oral
Clonazepam 2 mg tablet 2 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6963).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074569.
3 Characterization of GABAA receptor function in human temporal cortical neurons. J Neurophysiol. 1996 Apr;75(4):1458-71.
4 Residual effect of a 7-amino metabolite of clonazepam on GABAA receptor function in the nucleus reticularis thalami of the rat. Epilepsia. 2008 Oct;49(10):1803-8.
5 Product monograph: Nexstellis (estetrol and drospirenone) oral tablets
6 BDDCS applied to over 900 drugs
7 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
9 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
11 Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
12 Hyperekplexia in neonates. Postgrad Med J. 2001 Sep;77(911):570-2.
13 Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7(2):69-75.
14 Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. Drug Metab Lett. 2007 Jan;1(1):3-5.
15 Characterization of Escherichia coli nitroreductase NfsB in the metabolism of nitrobenzodiazepines. Biochem Pharmacol. 2009 Jul 1;78(1):96-103.
16 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
17 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
18 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
19 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
20 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
21 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
22 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
23 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
24 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
25 Arylamine N-acetyltransferase in human red blood cells. Biochem Pharmacol. 1992 Sep 25;44(6):1099-104.
26 A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther. 1993 Aug;54(2):134-41.
27 Effect of H2-receptor antagonists on rat liver cytosolic acetyl CoA:arylamine N-acetyltransferase activity. Drug Metab Dispos. 1992 Jan-Feb;20(1):74-8.
28 Crystallization and preliminary X-ray characterization of arylamine N-acetyltransferase C (BanatC) from Bacillus anthracis. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Oct 1;63(Pt 10):862-4.
29 Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos. 2005 Jul;33(7):969-76.
30 Genetic analysis of bacterial acetyltransferases: identification of amino acids determining the specificities of the aminoglycoside 6'-N-acetyltransferase Ib and IIa proteins. J Bacteriol. 1992 May;174(10):3196-203.
31 NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis. Z Gastroenterol. 2008 Mar;46(3):259-65.
32 Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities. Eur J Clin Pharmacol. 1999 Jan;54(11):869-76.
33 Aminoglycoside resistance resulting from tight drug binding to an altered aminoglycoside acetyltransferase. Antimicrob Agents Chemother. 2003 May;47(5):1577-83.
34 Prizidilol, an antihypertensive with precapillary vasodilator and beta-adrenoceptor blocking actions, in primary hypertension. Clin Pharmacol Ther. 1981 May;29(5):588-93.
35 Conversion of NfsB, a minor Escherichia coli nitroreductase, to a flavin reductase similar in biochemical properties to FRase I, the major flavin reductase in Vibrio fischeri, by a single amino acid substitution. J Bacteriol. 1996 Aug;178(15):4731-3.
36 Structure-based development of bacterial nitroreductase against nitrobenzodiazepine-induced hypnosis. Biochem Pharmacol. 2012 Jun 15;83(12):1690-9.
37 Metronidazole (flagyl) and misonidazole (Ro-07-0582): reduction by facultative anaerobes and cytotoxic action on hypoxic bacteria and mammalian cells in vivo. Br J Cancer Suppl. 1978 Jun;3:132-5.
38 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
39 Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605.
40 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
41 Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents. 2003 Sep;22(3):318-31.
42 Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new se... J Med Chem. 1997 Sep 12;40(19):3109-18.
43 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
44 DP-VPA D-Pharm. Curr Opin Investig Drugs. 2002 Jun;3(6):921-3.
45 Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9.
46 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
47 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
48 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
49 Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." Epilepsia 37 (1996): 253-7. [PMID: 8598183]
50 Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35. [PMID: 19188]
51 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
52 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
53 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
54 Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
55 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
56 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
57 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
58 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
59 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
60 Cerner Multum, Inc. "Australian Product Information.".
61 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
62 Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
63 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
64 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
65 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
66 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
67 Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
68 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
69 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
70 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
71 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
72 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
73 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
74 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
75 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
76 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
77 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
78 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
79 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
80 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
81 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
82 Product Information. Gattex (teduglutide). NPS Pharmaceuticals, Bedminster, NJ.
83 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
84 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
85 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
86 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
87 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
88 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
89 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
90 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
91 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
92 Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M "Long-term efficacy and toxicity of high- and low-dose amiodarone regimens." J Clin Pharmacol 29 (1989): 418-23. [PMID: 2661600]